magnesium hydroxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4244 1309-42-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • magnesium hydroxide
An inorganic compound that occurs in nature as the mineral brucite. It acts as an antacid with cathartic effects.
  • Molecular weight: 58.32
  • Formula: H2MgO2
  • CLOGP: -1.75
  • LIPINSKI: None
  • HAC: 2
  • HDO: 2
  • TPSA: 40.46
  • ALOGS:
  • ROTB: 0

Drug dosage:

DoseUnitRoute
3 g O
0.50 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 58
kinase-selectivity-class ACVRL1,BMX,BRAF,GRK2,MAP2K6,MAP3K14,PIK3CD,PIK3CG,PRKDC,TGFBR1 10
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 2000 FDA MCNEIL CONS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 1048.09 11.33 338 30272 16606 90581231
Creatinine renal clearance decreased 1039.77 11.33 345 30265 18554 90579283
Orthostatic hypotension 1011.33 11.33 417 30193 41410 90556427
Blood calcium decreased 942.51 11.33 362 30248 29820 90568017
Sedation 909.20 11.33 403 30207 47768 90550069
Cognitive disorder 835.46 11.33 426 30184 68981 90528856
Balance disorder 727.63 11.33 436 30174 96644 90501193
Depressed level of consciousness 643.49 11.33 364 30246 72420 90525417
Hypotension 377.58 11.33 505 30105 324892 90272945
Constipation 337.17 11.33 443 30167 279952 90317885
Fall 320.17 11.33 578 30032 481232 90116605
Mobility decreased 290.29 11.33 389 30221 250345 90347492
Toxicity to various agents 229.72 11.33 375 30235 287471 90310366
Vaginal flatulence 147.19 11.33 76 30534 12562 90585275
Proctitis 136.45 11.33 77 30533 15182 90582655
Female genital tract fistula 130.30 11.33 79 30531 17789 90580048
Radiculopathy 125.22 11.33 78 30532 18427 90579410
Vaginal discharge 124.08 11.33 79 30531 19385 90578452
Creatinine renal clearance increased 119.12 11.33 44 30566 3237 90594600
Chronic sinusitis 111.94 11.33 80 30530 23722 90574115
Renal function test abnormal 100.68 11.33 49 30561 7142 90590695
Oral candidiasis 91.69 11.33 84 30526 35371 90562466
Paraesthesia oral 87.76 11.33 78 30532 31581 90566256
Multiple drug therapy 81.18 11.33 42 30568 6967 90590870
Pain 79.99 11.33 592 30018 995749 89602088
Macular degeneration 77.53 11.33 79 30531 37891 90559946
Drug ineffective 67.02 11.33 242 30368 1384056 89213781
Procedural pain 65.56 11.33 68 30542 33292 90564545
Haematochezia 61.32 11.33 96 30514 70817 90527020
Rectal haemorrhage 60.71 11.33 104 30506 82640 90515197
Frequent bowel movements 60.63 11.33 85 30525 56850 90540987
Colitis 56.78 11.33 92 30518 69850 90527987
Colitis ulcerative 55.49 11.33 84 30526 60182 90537655
Hypersensitivity 47.64 11.33 50 30560 454627 90143210
Condition aggravated 46.71 11.33 81 30529 595464 90002373
Anaemia 46.04 11.33 238 30372 352564 90245273
Infusion site reaction 39.56 11.33 40 30570 18999 90578838
Musculoskeletal stiffness 39.18 11.33 26 30584 296506 90301331
Completed suicide 37.65 11.33 3 30607 145055 90452782
Alopecia 37.29 11.33 69 30541 495002 90102835
Arthralgia 35.59 11.33 139 30471 778383 89819454
Infection 34.46 11.33 43 30567 362051 90235786
Abdominal pain 32.58 11.33 237 30373 395484 90202353
Hypermagnesaemia 31.99 11.33 13 30597 1236 90596601
Exposure during pregnancy 31.36 11.33 21 30589 238389 90359448
Rash 30.99 11.33 151 30459 795949 89801888
Contraindicated product administered 30.47 11.33 38 30572 320101 90277736
Arthropathy 30.35 11.33 48 30562 366194 90231643
Joint swelling 29.83 11.33 80 30530 503220 90094617
Abdominal discomfort 28.95 11.33 75 30535 477253 90120584
Systemic lupus erythematosus 27.62 11.33 50 30560 361846 90235991
Dementia 27.47 11.33 37 30573 23824 90574013
Polyglandular disorder 24.47 11.33 7 30603 227 90597610
Drug hypersensitivity 24.33 11.33 78 30532 463531 90134306
Hypoparathyroidism 24.21 11.33 10 30600 991 90596846
Injection site pain 23.24 11.33 15 30595 173684 90424153
Swelling 23.05 11.33 69 30541 418989 90178848
Hand deformity 21.68 11.33 42 30568 296320 90301517
Drug intolerance 21.65 11.33 78 30532 447513 90150324
Intentional overdose 21.63 11.33 3 30607 93831 90504006
Taste disorder 21.31 11.33 57 30553 61489 90536348
Wound 21.25 11.33 44 30566 302936 90294901
Rheumatoid factor positive 20.15 11.33 17 30593 171633 90426204
Failure to thrive 19.95 11.33 19 30591 8392 90589445
Bladder disorder 19.46 11.33 21 30589 10751 90587086
Anaemia folate deficiency 18.64 11.33 7 30603 539 90597298
Sinusitis 18.50 11.33 57 30553 343031 90254806
Endocrine disorder 17.97 11.33 8 30602 952 90596885
Chronic kidney disease 17.90 11.33 47 30563 50144 90547693
Fatigue 17.69 11.33 279 30331 1153744 89444093
Synovitis 17.62 11.33 55 30555 329697 90268140
Pruritus 17.57 11.33 109 30501 541416 90056421
Pericarditis 17.49 11.33 41 30569 270110 90327727
Rheumatoid arthritis 16.99 11.33 64 30546 362550 90235287
Weight increased 16.96 11.33 78 30532 417849 90179988
Product use issue 16.95 11.33 56 30554 329863 90267974
Product quality issue 16.83 11.33 62 30548 79263 90518574
Urinary tract infection 16.63 11.33 167 30443 305465 90292372
Ill-defined disorder 16.50 11.33 23 30587 184868 90412969
Treatment failure 16.02 11.33 51 30559 303877 90293960
Discomfort 15.93 11.33 44 30566 274291 90323546
Lower respiratory tract infection 15.47 11.33 39 30571 250620 90347217
Gastrointestinal disorder 15.03 11.33 41 30569 256646 90341191
Back injury 14.96 11.33 42 30568 46580 90551257
Arthritis 14.74 11.33 21 30589 167294 90430543
Pemphigus 14.48 11.33 59 30551 326805 90271032
Blepharospasm 14.08 11.33 46 30564 55399 90542438
Chronic hepatitis 13.66 11.33 7 30603 1138 90596699
Asthma 13.21 11.33 40 30570 242120 90355717
Leukocytosis 13.13 11.33 31 30579 30959 90566878
Mental status changes 13.13 11.33 39 30571 44640 90553197
Therapeutic product effect incomplete 13.09 11.33 111 30499 193785 90404052
Neck pain 12.88 11.33 74 30536 113889 90483948
Anal incontinence 12.69 11.33 21 30589 16209 90581628
Psoriasis 12.57 11.33 19 30591 147735 90450102
Injection site erythema 12.51 11.33 9 30601 98493 90499344
Glossodynia 12.49 11.33 61 30549 321718 90276119
C-reactive protein abnormal 12.24 11.33 15 30595 127414 90470423
Urinary incontinence 12.21 11.33 34 30576 37532 90560305
Off label use 11.82 11.33 283 30327 1101969 89495868
Drug abuse 11.73 11.33 57 30553 82290 90515547
Dyspepsia 11.61 11.33 110 30500 198050 90399787
COVID-19 11.43 11.33 25 30585 168818 90429019
Maternal exposure during pregnancy 11.39 11.33 73 30537 359990 90237847

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Constipation 64.70 14.48 140 11626 162151 42447418
Abdominal pain 40.51 14.48 130 11636 190341 42419228
Sepsis 35.31 14.48 128 11638 199206 42410363
Hypermagnesaemia 32.54 14.48 9 11757 317 42609252
Blood phosphorus increased 29.94 14.48 26 11740 12499 42597070
Toxicity to various agents 29.79 14.48 13 11753 229123 42380446
Appendicolith 28.33 14.48 26 11740 13430 42596139
Supraventricular tachycardia 28.14 14.48 25 11741 12383 42597186
Pneumonia 27.09 14.48 204 11562 421945 42187624
Drug ineffective 27.01 14.48 87 11679 630110 41979459
Vomiting 25.80 14.48 152 11614 289571 42319998
Myasthenia gravis 24.34 14.48 26 11740 16111 42593458
Appendicitis 20.75 14.48 27 11739 20586 42588983
Normochromic normocytic anaemia 20.09 14.48 18 11748 9013 42600556
Hyperphosphataemia 19.70 14.48 21 11745 12983 42596586
Ventricular fibrillation 19.46 14.48 32 11734 30091 42579478
Blood uric acid increased 18.26 14.48 22 11744 15525 42594044
Anaemia 17.66 14.48 135 11631 280143 42329426
Ascites 17.17 14.48 44 11722 56634 42552935
Chronic obstructive pulmonary disease 17.10 14.48 47 11719 63067 42546502
Iron deficiency 17.00 14.48 18 11748 11043 42598526
Cardiogenic shock 16.80 14.48 33 11733 35607 42573962
Drug therapy 16.79 14.48 14 11752 6366 42603203
Plasma cell myeloma 16.61 14.48 39 11727 47539 42562030
Analgesic therapy 16.52 14.48 14 11752 6510 42603059
Mental status changes 16.34 14.48 36 11730 42079 42567490
Nausea 16.24 14.48 174 11592 396625 42212944
Urinary tract infection 16.07 14.48 62 11704 99222 42510347
Muscle spasticity 15.97 14.48 14 11752 6808 42602761
Atelectasis 15.92 14.48 23 11743 19338 42590231
Sleep disorder therapy 15.85 14.48 14 11752 6880 42602689
Blood cholesterol increased 15.41 14.48 27 11739 26714 42582855
Neuralgia 14.92 14.48 26 11740 25621 42583948
Heterotaxia 14.63 14.48 4 11762 135 42609434
Bacterial infection 14.60 14.48 27 11739 27852 42581717
Hypophosphataemia 14.55 14.48 23 11743 20922 42588647

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 1035.86 11.62 348 36866 19507 110532578
Creatinine renal clearance decreased 1027.01 11.62 354 36860 21461 110530624
Blood calcium decreased 903.60 11.62 368 36846 35477 110516608
Orthostatic hypotension 846.39 11.62 423 36791 65826 110486259
Cognitive disorder 789.70 11.62 443 36771 87068 110465017
Sedation 788.61 11.62 410 36804 69273 110482812
Balance disorder 665.09 11.62 440 36774 116120 110435965
Depressed level of consciousness 543.49 11.62 383 36831 111895 110440190
Constipation 344.34 11.62 507 36707 357279 110194806
Mobility decreased 314.31 11.62 393 36821 237029 110315056
Hypotension 280.88 11.62 573 36641 523276 110028809
Fall 269.59 11.62 613 36601 602869 109949216
Vaginal flatulence 150.31 11.62 76 37138 12068 110540017
Female genital tract fistula 136.30 11.62 79 37135 16440 110535645
Proctitis 131.89 11.62 78 37136 16849 110535236
Vaginal discharge 127.82 11.62 78 37136 17830 110534255
Radiculopathy 124.81 11.62 79 37135 19257 110532828
Creatinine renal clearance increased 115.01 11.62 44 37170 3581 110548504
Pain 114.72 11.62 627 36587 954328 109597757
Macular degeneration 111.88 11.62 77 37137 21582 110530503
Toxicity to various agents 109.61 11.62 383 36831 480172 110071913
Chronic sinusitis 101.73 11.62 77 37137 25007 110527078
Renal function test abnormal 93.54 11.62 50 37164 8896 110543189
Oral candidiasis 84.24 11.62 89 37125 44671 110507414
Paraesthesia oral 81.94 11.62 77 37137 33594 110518491
Multiple drug therapy 76.03 11.62 42 37172 7972 110544113
Drug ineffective 70.51 11.62 269 36945 1520271 109031814
Procedural pain 62.15 11.62 68 37146 35497 110516588
Hypermagnesaemia 52.56 11.62 20 37194 1603 110550482
Completed suicide 50.64 11.62 10 37204 242371 110309714
Frequent bowel movements 49.04 11.62 87 37127 71303 110480782
Abdominal pain 47.36 11.62 315 36899 512674 110039411
Colitis ulcerative 45.27 11.62 88 37126 77275 110474810
Anaemia 44.66 11.62 326 36888 546760 110005325
Infusion site reaction 44.10 11.62 41 37173 17641 110534444
Rectal haemorrhage 41.79 11.62 111 37103 119722 110432363
Colitis 40.05 11.62 99 37115 102224 110449861
Haematochezia 36.29 11.62 103 37111 115421 110436664
Hypersensitivity 34.07 11.62 52 37162 403946 110148139
Condition aggravated 32.60 11.62 132 37082 734704 109817381
Intentional overdose 30.97 11.62 4 37210 132497 110419588
Arthralgia 29.80 11.62 148 37066 779484 109772601
Rash 28.51 11.62 161 37053 820803 109731282
Infection 28.30 11.62 49 37165 362151 110189934
Blood phosphorus increased 28.12 11.62 31 37183 16309 110535776
Dementia 26.27 11.62 42 37172 31631 110520454
Joint swelling 24.73 11.62 72 37142 442773 110109312
Polyglandular disorder 24.15 11.62 7 37207 239 110551846
Pruritus 23.01 11.62 109 37105 581451 109970634
Appendicolith 22.75 11.62 26 37188 14229 110537856
Musculoskeletal stiffness 21.72 11.62 38 37176 279784 110272301
Myelosuppression 21.68 11.62 3 37211 94337 110457748
Off label use 20.74 11.62 368 36846 1499817 109052268
Bladder disorder 20.69 11.62 22 37192 11115 110540970
Injection site pain 20.26 11.62 18 37196 177904 110374181
Arthritis 20.26 11.62 16 37198 167570 110384515
Exposure during pregnancy 20.22 11.62 16 37198 167408 110384677
Hypoparathyroidism 20.18 11.62 10 37204 1520 110550565
Product quality issue 19.65 11.62 64 37150 77235 110474850
Failure to thrive 18.75 11.62 23 37191 13551 110538534
Urinary tract infection 18.35 11.62 179 37035 326103 110225982
Taste disorder 18.33 11.62 56 37158 65331 110486754
Mental status changes 17.56 11.62 61 37153 76061 110476024
Sepsis 17.16 11.62 177 37037 327169 110224916
Weight increased 16.97 11.62 78 37136 419566 110132519
Anaemia folate deficiency 16.97 11.62 7 37207 694 110551391
Ascites 16.95 11.62 69 37145 92739 110459346
Asthma 16.82 11.62 37 37177 250254 110301831
Back injury 16.61 11.62 44 37170 47355 110504730
Dyspepsia 16.22 11.62 115 37099 190850 110361235
Atelectasis 15.95 11.62 37 37177 36675 110515410
Alopecia 15.84 11.62 66 37148 364687 110187398
Myasthenia gravis 15.79 11.62 27 37187 21484 110530601
Contraindicated product administered 15.64 11.62 38 37176 248229 110303856
Hypercholesterolaemia 15.39 11.62 66 37148 90771 110461314
Hyperphosphataemia 15.37 11.62 23 37191 16358 110535727
Suicide attempt 15.04 11.62 8 37206 103386 110448699
Loss of personal independence in daily activities 15.00 11.62 17 37197 150003 110402082
Chronic kidney disease 14.96 11.62 58 37156 76233 110475852
Neck pain 14.75 11.62 81 37133 123049 110429036
Blepharospasm 14.47 11.62 46 37168 54805 110497280
Injection site erythema 14.13 11.62 7 37207 94169 110457916
Hypophosphataemia 13.93 11.62 33 37181 33149 110518936
Endocrine disorder 13.81 11.62 7 37207 1117 110550968
Acute respiratory failure 13.78 11.62 56 37158 75204 110476881
Arthropathy 13.78 11.62 50 37164 287472 110264613
Interstitial lung disease 13.70 11.62 16 37198 139318 110412767
Fatigue 13.54 11.62 309 36905 1215649 109336436
Chronic hepatitis 13.37 11.62 8 37206 1764 110550321
Supraventricular tachycardia 13.34 11.62 27 37187 24395 110527690
Normochromic normocytic anaemia 13.22 11.62 19 37195 13038 110539047
Diarrhoea 13.13 11.62 288 36926 1139217 109412868
Analgesic therapy 12.85 11.62 14 37200 7270 110544815
Drug therapy 12.84 11.62 14 37200 7277 110544808
C-reactive protein abnormal 12.63 11.62 15 37199 129680 110422405
Sleep disorder therapy 12.56 11.62 14 37200 7457 110544628
Hepatotoxicity 12.45 11.62 3 37211 63397 110488688
Influenza 12.20 11.62 24 37190 169077 110383008
Ventricular fibrillation 12.16 11.62 36 37178 41277 110510808
Rhinorrhoea 12.16 11.62 10 37204 102656 110449429
Sinusitis 12.07 11.62 55 37159 296633 110255452
Iron deficiency 12.02 11.62 22 37192 18454 110533631
Product use issue 11.97 11.62 59 37155 311636 110240449
Cardiac failure congestive 11.72 11.62 89 37125 150911 110401174

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02AA04 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
ANTACIDS
Magnesium compounds
ATC G04BX01 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Other urologicals
MeSH PA D000863 Antacids
MeSH PA D005765 Gastrointestinal Agents
CHEBI has role CHEBI:65265 antacids
CHEBI has role CHEBI:79314 flame retardants

Related Drugs by ATC class:

A02AA Magnesium compounds 4 drugs
magnesium carbonatemagnesium oxidemagnesium peroxidemagnesium silicate
G04BX Other urologicals 10 drugs
acetohydroxamic aciddapoxetinedimethyl sulfoxidemethenaminepentosan polysulfatephenazopyridinephenyl salicylatesalicylic acidsuccinimidetiopronin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Constipation indication 14760008 DOID:2089
Heartburn indication 16331000
Indigestion indication 162031009
Gastroesophageal reflux disease indication 235595009 DOID:8534
Incomplete passage of stool indication 249515001
Gastric Hypersecretory Conditions indication
Heartburn Prevention indication
Hiatal Hernia with Reflux Esophagitis indication
Hypocalcemia off-label use 5291005
Upper gastrointestinal hemorrhage off-label use 37372002
Duodenal ulcer disease off-label use 51868009 DOID:1724
Zollinger-Ellison syndrome off-label use 53132006 DOID:0050782
Multiple endocrine adenomas off-label use 60549007
Osteoporosis off-label use 64859006 DOID:11476
Postmenopausal osteoporosis off-label use 102447009
Systemic mast cell disease off-label use 397016004 DOID:349
Gastric ulcer off-label use 397825006 DOID:10808
Stress-Related GI Mucosal Bleeding Prevention off-label use
Prevention of Stress Ulcer off-label use
Maintenance of Healing Duodenal Ulcer off-label use
Renal Osteodystrophy with Hyperphosphatemia off-label use
Dyspepsia Prevention off-label use
Hypophosphatemia contraindication 4996001
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
Fecal impaction contraindication 44635007
Diarrhea contraindication 62315008
Hypercalcemia contraindication 66931009 DOID:12678
Hypermagnesemia contraindication 66978005
Hyperparathyroidism contraindication 66999008 DOID:13543
Hemorrhoids contraindication 70153002 DOID:9746
Appendicitis contraindication 74400008 DOID:8337
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Gastrointestinal obstruction contraindication 126765001
Impaired renal function disorder contraindication 197663003
Osteolysis contraindication 203522001
Disease of liver contraindication 235856003 DOID:409
Chronic diarrhea contraindication 236071009
Aluminum intoxication contraindication 236546003
Malignant tumor of stomach contraindication 363349007 DOID:10534




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4017693 VUID
N0000146067 NUI
D00731 KEGG_DRUG
4017693 VANDF
C0024476 UMLSCUI
CHEBI:6637 CHEBI
CHEMBL1200718 ChEMBL_ID
D008276 MESH_DESCRIPTOR_UI
DB09104 DRUGBANK_ID
NBZ3QY004S UNII
73981 PUBCHEM_CID
6581 RXNORM
5013 MMSL
5579 MMSL
d00982 MMSL
001119 NDDF
001186 NDDF
387337001 SNOMEDCT_US
60468008 SNOMEDCT_US
NBZ3QY004S INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Good Sense Dual Action Complete HUMAN OTC DRUG LABEL 3 0113-0032 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
Good Sense Dual Action Complete HUMAN OTC DRUG LABEL 3 0113-0032 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
injoy heartburn relief HUMAN OTC DRUG LABEL 3 0113-6023 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
injoy heartburn relief HUMAN OTC DRUG LABEL 3 0113-6023 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
GOOD SENSE DUAL ACTION COMPLETE HUMAN OTC DRUG LABEL 3 0113-7050 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
GOOD SENSE DUAL ACTION COMPLETE HUMAN OTC DRUG LABEL 3 0113-7050 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
Milk of Magnesia HUMAN OTC DRUG LABEL 1 0121-0431 SUSPENSION 400 mg ORAL OTC Monograph Drug 15 sections
Milk of Magnesia HUMAN OTC DRUG LABEL 1 0121-0431 SUSPENSION 400 mg ORAL OTC Monograph Drug 15 sections
Milk of Magnesia Concentrate HUMAN OTC DRUG LABEL 1 0121-0940 SUSPENSION 2400 mg ORAL OTC Monograph Drug 16 sections
Milk of Magnesia Concentrate HUMAN OTC DRUG LABEL 1 0121-0940 SUSPENSION 2400 mg ORAL OTC Monograph Drug 16 sections
Mag-AL Liquid HUMAN OTC DRUG LABEL 2 0121-1760 SUSPENSION 200 mg ORAL OTC Monograph Drug 14 sections
Mag-AL Liquid HUMAN OTC DRUG LABEL 2 0121-1760 SUSPENSION 200 mg ORAL OTC Monograph Drug 14 sections
Mag-AL Plus HUMAN OTC DRUG LABEL 3 0121-1761 SUSPENSION 200 mg ORAL OTC Monograph Drug 14 sections
Mag-AL Plus HUMAN OTC DRUG LABEL 3 0121-1761 SUSPENSION 200 mg ORAL OTC Monograph Drug 14 sections
Mag-AL PlusXS HUMAN OTC DRUG LABEL 3 0121-1762 SUSPENSION 400 mg ORAL OTC Monograph Drug 15 sections
Mag-AL PlusXS HUMAN OTC DRUG LABEL 3 0121-1762 SUSPENSION 400 mg ORAL OTC Monograph Drug 15 sections
Pedia-Lax HUMAN OTC DRUG LABEL 1 0132-0655 TABLET, CHEWABLE 400 mg ORAL OTC Monograph Drug 12 sections
Pedia-Lax HUMAN OTC DRUG LABEL 1 0132-0655 TABLET, CHEWABLE 400 mg ORAL OTC Monograph Drug 12 sections
PHILLIPS ORIGINAL MILK OF MAGNESIA HUMAN OTC DRUG LABEL 1 0280-0030 LIQUID 1200 mg ORAL OTC Monograph Drug 14 sections
PHILLIPS FRESH MINT MILK OF MAGNESIA HUMAN OTC DRUG LABEL 1 0280-0031 LIQUID 1200 mg ORAL OTC Monograph Drug 15 sections
Phillips Milk Of Magnesia Wild Cherry HUMAN OTC DRUG LABEL 1 0280-0032 LIQUID 1200 mg ORAL OTC Monograph Drug 15 sections
Heartburn Plus Gas Relief Chewable Multi Symptom HUMAN OTC DRUG LABEL 3 0363-0107 TABLET, CHEWABLE 135 mg ORAL OTC monograph final 12 sections
Acid Reducer Complete HUMAN OTC DRUG LABEL 3 0363-0511 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
Acid Reducer Complete HUMAN OTC DRUG LABEL 3 0363-0511 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
MILK OF MAGNESIA HUMAN OTC DRUG LABEL 1 0363-0647 SUSPENSION 1200 mg ORAL OTC Monograph Drug 10 sections
MILK OF MAGNESIA HUMAN OTC DRUG LABEL 1 0363-0647 SUSPENSION 1200 mg ORAL OTC Monograph Drug 10 sections
MILK OF MAGNESIA HUMAN OTC DRUG LABEL 1 0363-0649 SUSPENSION 1200 mg ORAL OTC Monograph Drug 10 sections
MILK OF MAGNESIA HUMAN OTC DRUG LABEL 1 0363-0649 SUSPENSION 1200 mg ORAL OTC Monograph Drug 10 sections
Acid Reducer Complete HUMAN OTC DRUG LABEL 3 0363-0713 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
Acid Reducer Complete HUMAN OTC DRUG LABEL 3 0363-0713 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections